$MGEN News
Last published 5y ago
- 5y agoVRDNMGENmiRagen Therapeutics Announces Company Name Change to Viridian Therapeutics and New Executive Appointments, Including Expansion of Leadership TeamGlobeNewswireJonathan Violin, Ph.D., M.B.A. appointed President, CEO and director Barrett Katz, M.D., M.B.A. joins Viridian as Chief Medical OfficerViridian is developing VRDN-001 and VRDN-002 for the treatment of...
- 5y agoMGENmiRagen Enters into License Agreement with Xencor for use of Xtend™ Antibody Technology for Investigational Antibodies to Treat Thyroid Eye DiseaseGlobeNewswireCompany obtains exclusive rights to develop and commercialize antibody therapeutics targeting insulin-like growth factor-1 receptor (IGF-1R) using Xencor’s Xtend™ half-life extension technology ...
- 6y agoMGENmiRagen Reports Third Quarter 2020 Financial Results and Provides Corporate UpdatesGlobeNewswireRecently completed acquisition of Viridian Therapeutics, including an anti-IGF-1R monoclonal antibody, VRDN-001, for the potential treatment of thyroid eye disease (TED)Private placement financing...
- 6y agoMGENmiRagen Therapeutics, Inc. Announces Acquisition of Viridian Therapeutics, Inc.GlobeNewswireAcquisition includes clinical stage anti-IGF-1R monoclonal antibody, VRDN-001, intended for the treatment of thyroid eye disease (TED) Company plans to use private placement financing proceeds of...
- 6y agoMGENmiRagen Announces Internal Review of Preliminary Topline Data for the Phase 2 SOLAR Clinical Trial of Cobomarsen in Patients with Cutaneous T-Cell Lymphoma (CTCL)GlobeNewswireBOULDER, Colo., Oct. 05, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted...
- 6y agoMGENmiRagen Announces Leadership Transition and Review of Strategic AlternativesGlobeNewswireLee Rauch appointed President and CEO, following resignation by William Marshall miRagen will undertake an in-depth review of its portfolio Ladenburg Thalmann engaged as financial advisor BOULDER,...
- 6y agoMGENmiRagen Announces Results of Meeting With FDA Regarding the Design of Pivotal Trial for Cobomarsen in ATLLGlobeNewswireBOULDER, Colo., Aug. 20, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary...
- 6y agoMGENmiRagen Reports Second Quarter 2020 Financial Results and Provides Business UpdatesGlobeNewswireProgress on next generation microRNA-29 mimic for use in pulmonary fibrosis (MRG-229) includes new preclinical data; additional NIH grant funding triggeredExploratory preclinical safety and...
- 6y agoMGENmiRagen to Present at the 2020 Wedbush PacGrow Healthcare Virtual ConferenceGlobeNewswireBOULDER, Colo., Aug. 04, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted...
- 6y agoMGENCobomarsen Receives Orphan Drug Designation From the U.S. FDA for the Treatment of T-cell LymphomaGlobeNewswireBOULDER, Colo., July 23, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted...
- 6y agoMGENmiRagen to Report Second Quarter 2020 Financial Results on August 5, 2020GlobeNewswireBOULDER, Colo., July 22, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted...
- 6y agoMGENmiRagen Regains Compliance With Nasdaq Listing RequirementsGlobeNewswireBOULDER, Colo., July 02, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted...
- 6y agoMGENmiRagen Announces Encouraging Preclinical Safety and Efficacy Data for its Next-generation miR-29 Replacement Product Candidate Intended for the Treatment of Idiopathic Pulmonary FibrosisGlobeNewswireBOULDER, Colo., June 22, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted...
- 6y agoMGENmiRagen Strengthens Leadership Team with Appointment of Lee Rauch as Chief Operating OfficerGlobeNewswireBOULDER, Colo., June 18, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted...
- 6y agoMGENmiRagen to Host a Key Opinion Leader Call on Idiopathic Pulmonary Fibrosis on Tuesday, June 23rdGlobeNewswireBOULDER, Colo., June 16, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted...
- 6y agoMGENmiRagen to Present at the Jefferies 2020 Virtual Global Healthcare ConferenceGlobeNewswireBOULDER, Colo., May 26, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted...
- 6y agoMGENmiRagen Reports First Quarter 2020 Financial Results and Provides Corporate UpdateGlobeNewswireNew ATLL data presented in the first quarter; Company plans to request a meeting with the FDA on a regulatory pathway for cobomarsen in ATLL during Q2 2020Additional NIH grant funding released in...
- 6y agoMGENmiRagen Reports Fourth Quarter and Full Year 2019 Financial ResultsGlobeNewswireCompleted enrollment of 37 patients in the Phase 2 SOLAR trial of cobomarsen in CTCL; expects to report topline data in Q3 2020Completed initial planned enrollment of the Phase 1 trial of cobomarsen...
- 6y agoMGENmiRagen Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants to Purchase Common StockGlobeNewswireBOULDER, Colo., Feb. 07, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted...
- 6y agoMGENmiRagen Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common StockGlobeNewswireBOULDER, Colo., Feb. 06, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted...
- 6y agoMGENmiRagen Therapeutics Announces Positive Data for Cobomarsen in Adult T-Cell Leukemia/lymphoma Patients With Residual DiseaseGlobeNewswireCobomarsen-treated adult T-cell leukemia/lymphoma (ATLL) patients with residual disease had a median survival time (MST) of 26 months compared with 7.4 months in a historical cohort- - - Median...
- 6y agoCNSPBCRXCLVSACHN+1Global Glioblastoma Multiforme Drugs Market Projected Could Reach $1.4 Billion By 2025PR NewswireBrain and other nervous system cancers are the 10th leading cause of death for men and women. The global Glioblastoma multiforme (GBM) drugs market...
- 6y agoMGENmiRagen Announces Major Changes to Company’s StrategyGlobeNewswireExpecting topline data in Q3 2020 from truncated Phase 2 SOLAR clinical trial of cobomarsen in CTCL Pursuing guidance from FDA on a clinical development plan for cobomarsen in ATLL; anticipate meeting...
- 7y agoMGENmiRagen Therapeutics to Report Third Quarter 2019 Financial Results and Host a Conference CallGlobeNewswireBOULDER, Colo., Oct. 22, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific...
- 7y agoMGENmiRagen Announces New Clinical Data Showing MRG-110 Positively Impacted Tissue Repair and New Blood Vessel GrowthGlobeNewswireData included in an oral presentation at the 15th annual meeting of the Oligonucleotide Therapeutics Society Data supports advancing MRG-110 into additional clinical studies BOULDER, Colo., Oct. ...
- 7y agoMGENmiRagen Therapeutics to Present a Corporate Overview at the Robert W. Baird & Co. 2019 Global Healthcare ConferenceGlobeNewswireBOULDER, Colo., Aug. 15, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific...
- 7y agoMGENmiRagen Therapeutics' (MGEN) CEO Bill Marshall on Q2 2019 Results - Earnings Call TranscriptEarnings Call Transcripts
- 7y agoMGENmiRagen Therapeutics, Inc. (MGEN) CEO Bill Marshall on Q1 2019 Results - Earnings Call TranscriptEarnings Call Transcripts
- 8y agoMGENMiragen Therapeutics, Inc. (MGEN) CEO William Marshall on Q2 2018 Results - Earnings Call TranscriptEarnings Call Transcripts
- 9y agoMGENmiRagen Therapeutics' (MGEN) CEO William Marshall on Q1 2017 Results - Earnings Call TranscriptEarnings Call Transcripts